Schedule of Investments (unaudited) September 30, 2022 | BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Common Stocks | ||||||||
Biotechnology — 18.6% | ||||||||
AbbVie, Inc. | 115,203 | $ | 15,461,395 | |||||
Affinivax, Inc., (Acquired 08/18/22, Cost: $0)(a)(b) | 6,331 | 84,645 | ||||||
Alkermes PLC(c) | 22,001 | 491,282 | ||||||
Alnylam Pharmaceuticals, Inc.(c) | 15,553 | 3,113,089 | ||||||
Ambrx Biopharma, Inc., ADR(c) | 43,409 | 46,882 | ||||||
Amgen, Inc.(d) | 67,126 | 15,130,200 | ||||||
Arcutis Biotherapeutics, Inc.(c) | 42,854 | 818,940 | ||||||
Argenx SE, ADR(c) | 7,321 | 2,584,679 | ||||||
Biogen, Inc.(c) | 20,607 | 5,502,069 | ||||||
BioMarin Pharmaceutical, Inc.(c) | 30,495 | 2,585,061 | ||||||
Blueprint Medicines Corp.(c) | 14,055 | 926,084 | ||||||
Cerevel Therapeutics Holdings, Inc.(c) | 16,785 | 474,344 | ||||||
Decibel Therapeutics, Inc.(c) | 46,884 | 162,219 | ||||||
Design Therapeutics, Inc.(c) | 13,967 | 233,528 | ||||||
Enanta Pharmaceuticals, Inc.(c) | 3,150 | 163,391 | ||||||
Exact Sciences Corp.(c) | 15,501 | 503,628 | ||||||
Genmab A/S(c) | 2,498 | 803,615 | ||||||
Genmab A/S, ADR(c) | 16,911 | 543,350 | ||||||
Gilead Sciences, Inc. | 157,239 | 9,700,074 | ||||||
Horizon Therapeutics PLC(c) | 22,617 | 1,399,766 | ||||||
Imago Biosciences, Inc.(c) | 47,824 | 719,751 | ||||||
Immuneering Corp., Class A(c)(e) | 14,456 | 207,010 | ||||||
Immunocore Holdings PLC, ADR(c) | 9,668 | 453,816 | ||||||
Incyte Corp.(c) | 26,918 | 1,793,816 | ||||||
Ionis Pharmaceuticals, Inc.(c) | 18,640 | 824,447 | ||||||
Karuna Therapeutics, Inc.(c) | 3,635 | 817,621 | ||||||
Legend Biotech Corp., ADR(c) | 14,146 | 577,157 | ||||||
Moderna, Inc.(c) | 29,223 | 3,455,620 | ||||||
Monte Rosa Therapeutics, Inc.(c) | 28,575 | 233,458 | ||||||
MoonLake Immunotherapeutics(c)(e) | 11,715 | 93,251 | ||||||
Neurocrine Biosciences, Inc.(c) | 23,254 | 2,469,807 | ||||||
PMV Pharmaceuticals, Inc.(c) | 17,490 | 208,131 | ||||||
Point Biopharma Global, Inc.(c)(e) | 27,000 | 208,710 | ||||||
Prothena Corp. PLC(c) | 8,734 | 529,542 | ||||||
PTC Therapeutics, Inc.(c) | 8,450 | 424,190 | ||||||
Regeneron Pharmaceuticals, Inc.(c) | 10,697 | 7,368,842 | ||||||
Revolution Medicines, Inc.(c) | 18,874 | 372,195 | ||||||
Rhythm Pharmaceuticals, Inc.(c) | 48,130 | 1,179,185 | ||||||
Sage Therapeutics, Inc.(c) | 21,680 | 848,989 | ||||||
Sarepta Therapeutics, Inc.(c) | 18,688 | 2,065,772 | ||||||
Seagen, Inc.(c) | 20,872 | 2,855,916 | ||||||
Sigilon Therapeutics, Inc.(c) | 19,555 | 9,875 | ||||||
Tenaya Therapeutics, Inc.(c) | 25,502 | 73,956 | ||||||
TScan Therapeutics, Inc.(c) | 29,940 | 91,317 | ||||||
Ultragenyx Pharmaceutical, Inc.(c) | 6,140 | 254,257 | ||||||
Vertex Pharmaceuticals, Inc.(c) | 41,974 | 12,153,152 | ||||||
|
| |||||||
101,018,024 | ||||||||
Diversified Financial Services(c) — 0.3% | ||||||||
Health Assurance Acquisition Corp., Class A | 90,235 | 900,545 | ||||||
Health Sciences Acquisitions Corp. 2 | 13,696 | 135,659 | ||||||
MedTech Acquisition Corp., Class A | 42,753 | 424,537 | ||||||
|
| |||||||
1,460,741 | ||||||||
Health Care Equipment & Supplies — 17.7% | ||||||||
Abbott Laboratories(d) | 194,667 | 18,835,979 | ||||||
ABIOMED, Inc.(c) | 14,359 | 3,527,432 | ||||||
Alcon, Inc.(c) | 53,199 | 3,095,118 | ||||||
Align Technology, Inc.(c) | 3,960 | 820,156 | ||||||
Bausch & Lomb Corp.(c)(e) | 75,830 | 1,163,232 |
Security | Shares | Value | ||||||
Health Care Equipment & Supplies (continued) | ||||||||
Baxter International, Inc. | 71,467 | $ | 3,849,213 | |||||
Boston Scientific Corp.(c) | 382,767 | 14,824,566 | ||||||
Cooper Cos., Inc.(c) | 5,056 | 1,334,278 | ||||||
DexCom, Inc.(c) | 52,400 | 4,220,296 | ||||||
Edwards Lifesciences Corp.(c) | 42,331 | 3,497,811 | ||||||
Glaukos Corp.(c) | 4,880 | 259,811 | ||||||
Insulet Corp.(c) | 8,685 | 1,992,339 | ||||||
Intuitive Surgical, Inc.(c) | 33,429 | 6,265,932 | ||||||
iRhythm Technologies, Inc.(c) | 2,280 | 285,638 | ||||||
Medtronic PLC | 124,589 | 10,060,562 | ||||||
Nevro Corp.(c) | 41,187 | 1,919,314 | ||||||
Novocure Ltd.(c) | 10,555 | 801,969 | ||||||
Omnicell, Inc.(c) | 6,425 | 559,168 | ||||||
Penumbra, Inc.(c) | 10,510 | 1,992,696 | ||||||
ResMed, Inc. | 20,674 | 4,513,134 | ||||||
Stryker Corp. | 52,497 | 10,632,742 | ||||||
Zimmer Biomet Holdings, Inc. | 14,617 | 1,528,207 | ||||||
|
| |||||||
95,979,593 | ||||||||
Health Care Providers & Services — 22.9% | ||||||||
Agiliti, Inc.(c) | 75,106 | 1,074,767 | ||||||
Amedisys, Inc.(c) | 22,677 | 2,194,907 | ||||||
AmerisourceBergen Corp. | 53,668 | 7,262,890 | ||||||
Centene Corp.(c) | 70,991 | 5,523,810 | ||||||
Cigna Corp. | 48,254 | 13,389,037 | ||||||
CVS Health Corp. | 36,785 | 3,508,185 | ||||||
Elevance Health, Inc.(d) | 35,882 | 16,299,040 | ||||||
Encompass Health Corp. | 43,989 | 1,989,622 | ||||||
Guardant Health, Inc.(c) | 11,675 | 628,465 | ||||||
HCA Healthcare, Inc. | 8,085 | 1,485,942 | ||||||
Henry Schein, Inc.(c) | 8,245 | 542,274 | ||||||
LHC Group, Inc.(c) | 20,224 | 3,309,860 | ||||||
McKesson Corp. | 23,385 | 7,947,860 | ||||||
Quest Diagnostics, Inc. | 45,124 | 5,536,264 | ||||||
UnitedHealth Group, Inc.(d) | 105,815 | 53,440,808 | ||||||
|
| |||||||
124,133,731 | ||||||||
Life Sciences Tools & Services — 11.2% | ||||||||
10X Genomics, Inc., Class A(c) | 10,520 | 299,610 | ||||||
Agilent Technologies, Inc. | 62,230 | 7,564,057 | ||||||
Avantor, Inc.(c) | 78,897 | 1,546,381 | ||||||
Danaher Corp. | 72,555 | 18,740,231 | ||||||
Icon PLC(c) | 8,210 | 1,508,834 | ||||||
IQVIA Holdings, Inc.(c) | 24,543 | 4,445,719 | ||||||
IsoPlexis Corp.(c)(e) | 30,336 | 52,178 | ||||||
Nautilus Biotechnology, Inc.(c) | 16,560 | 35,107 | ||||||
QIAGEN NV(c) | 25,121 | 1,036,995 | ||||||
Rapid Micro Biosystems, Inc., Class A(c)(e) | 20,561 | 66,412 | ||||||
Thermo Fisher Scientific, Inc.(f) | 43,313 | 21,967,920 | ||||||
Waters Corp.(c) | 10,760 | 2,900,143 | ||||||
West Pharmaceutical Services, Inc.(c) | 2,815 | 692,715 | ||||||
|
| |||||||
60,856,302 | ||||||||
Pharmaceuticals — 23.4% | ||||||||
AstraZeneca PLC | 74,426 | 8,181,607 | ||||||
AstraZeneca PLC, ADR | 24,607 | 1,349,448 | ||||||
Bristol-Myers Squibb Co. | 67,526 | 4,800,423 | ||||||
Catalent, Inc.(c) | 15,275 | 1,105,299 | ||||||
Daiichi Sankyo Co. Ltd. | 104,800 | 2,929,249 | ||||||
Eli Lilly & Co. | 87,986 | 28,450,273 | ||||||
Hansoh Pharmaceutical Group Co. Ltd.(g) | 882,438 | 1,393,038 | ||||||
Johnson & Johnson(d)(f) | 171,201 | 27,967,395 | ||||||
Merck & Co., Inc.(d) | 217,194 | 18,704,747 |
1 |
|
Schedule of Investments (unaudited) (continued) September 30, 2022 | BlackRock Health Sciences Trust (BME) (Percentages shown are based on Net Assets) |
Security | Shares | Value | ||||||
Pharmaceuticals (continued) | ||||||||
Pfizer, Inc.(d) | 367,931 | $ | 16,100,661 | |||||
Roche Holding AG(c) | 8,551 | 2,783,629 | ||||||
Sanofi(c) | 24,587 | 1,872,213 | ||||||
Zoetis, Inc.(c) | 74,312 | 11,019,727 | ||||||
|
| |||||||
126,657,709 | ||||||||
|
| |||||||
Total Common Stocks — 94.1% | 510,106,100 | |||||||
|
| |||||||
Benefical Interest (000) | ||||||||
Other Interests | ||||||||
Pharmaceuticals — 0.0% | ||||||||
Afferent Pharmaceuticals, Inc.(a)(b)(h) | $ | 190 | 148,325 | |||||
|
| |||||||
Total Other Interests — 0.0% | 148,325 | |||||||
|
| |||||||
Shares | ||||||||
Preferred Securities | ||||||||
Preferred Stocks — 0.8%(a)(b) | ||||||||
Biotechnology — 0.2% | ||||||||
Cellarity, Inc., Series B, (Acquired 01/15/21, Cost: $265,002) | 44,167 | 176,668 | ||||||
Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, Cost: $224,200) | 190,000 | 233,700 | ||||||
Laronde, Inc., Series B, (Acquired 07/28/21, Cost: $590,800) | 21,100 | 531,720 | ||||||
Neurogene, Inc., Series B, (Acquired 12/14/20, Cost: $260,568) | 106,790 | 260,568 | ||||||
|
| |||||||
1,202,656 | ||||||||
Health Care Equipment & Supplies — 0.3% | ||||||||
Exo Imaging, Inc., Series C, (Acquired 06/24/21, Cost: $595,999) | 101,741 | 389,668 | ||||||
Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: $1,070,001) | 367,395 | 1,039,728 | ||||||
Quanta Dialysis Technologies Ltd., Series D, (Acquired 06/18/21, Cost: $515,758) | 4,243,029 | 312,678 | ||||||
Swift Health Systems, Inc., Series D, (Acquired 08/27/21, Cost: $286,998) | 92,580 | 186,086 | ||||||
|
| |||||||
1,928,160 | ||||||||
Pharmaceuticals — 0.1% | ||||||||
Insitro, Inc., Series C, (Acquired 03/10/21, Cost: $560,000) | 30,616 | 420,051 | ||||||
|
| |||||||
Software — 0.2% | ||||||||
Carbon Health Technologies, Inc., (Acquired 07/09/21, Cost: $907,000) | 907 | 907,209 | ||||||
|
| |||||||
4,458,076 | ||||||||
|
| |||||||
Total Preferred Securities — 0.8% | 4,458,076 | |||||||
|
| |||||||
Warrants | ||||||||
Diversified Financial Services — 0.0% | ||||||||
Health Assurance Acquisition Corp., (Issued 01/04/21, Exercisable 01/04/22, 1 Share for 1 Warrant, Expires 11/12/25, Strike Price USD 11.50)(c) | 12,859 | 386 | ||||||
|
|
Security | Shares | Value | ||||||
Health Care Providers & Services — 0.0% | ||||||||
CareMax, Inc., (Issued/Exercisable 09/15/20, 1 Share for 1 Warrant, Expires 07/16/25, Strike Price USD 11.50)(c) | 4,201 | $ | 6,889 | |||||
|
| |||||||
Pharmaceuticals — 0.0% | ||||||||
Nuvation Bio, Inc., (Issued/Exercisable 08/17/20, 1 Share for 1 Warrant, Expires 07/07/27, Strike Price USD 11.50)(c) | 4,050 | 648 | ||||||
|
| |||||||
Total Warrants — 0.0% | 7,923 | |||||||
|
| |||||||
Total Long-Term Investments — 94.9% | 514,720,424 | |||||||
|
| |||||||
Short-Term Securities | ||||||||
Money Market Funds — 5.0% | ||||||||
BlackRock Liquidity Funds, T-Fund, Institutional Class, 2.79%(i)(j) | 26,612,384 | 26,612,384 | ||||||
SL Liquidity Series, LLC, Money Market Series, 3.29%(i)(j)(k) | 694,019 | 694,019 | ||||||
|
| |||||||
Total Short-Term Securities — 5.0% | 27,306,403 | |||||||
|
| |||||||
Total Investments Before Options Written — 99.9% |
| 542,026,827 | ||||||
|
| |||||||
Options Written — (0.5)% | (3,181,457 | ) | ||||||
|
| |||||||
Total Investments, Net of Options Written — 99.4% |
| 538,845,370 | ||||||
Other Assets Less Liabilities — 0.6% | 3,349,741 | |||||||
|
| |||||||
Net Assets — 100.0% | $ | 542,195,111 | ||||||
|
|
(a) | Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. |
(b) | Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $4,691,046, representing 0.9% of its net assets as of period end, and an original cost of $5,276,326. |
(c) | Non-income producing security. |
(d) | All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. |
(e) | All or a portion of this security is on loan. |
(f) | All or a portion of the security has been pledged as collateral in connection with outstanding OTC derivatives. |
(g) | Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. |
(h) | Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities. |
(i) | Affiliate of the Trust. |
(j) | Annualized 7-day yield as of period end. |
(k) | All or a portion of this security was purchased with the cash collateral from loaned securities. |
S C H E D U L E O F I N V E S T M E N T S | 2 |
Schedule of Investments (unaudited) (continued) September 30, 2022 | BlackRock Health Sciences Trust (BME) |
For Trust compliance purposes, the Trust’s industry classifications refer to one or more of the industry sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such industry sub-classifications for reporting ease.
Affiliates
Investments in issuers considered to be affiliate(s) of the Trust during the period ended September 30, 2022 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:
Affiliated Issuer | Value at 12/31/21 | Purchases at Cost | Proceeds from Sales | Net Realized Gain (Loss) | Change in Unrealized Appreciation (Depreciation) | Value at 09/30/22 | Shares Held at 09/30/22 | Income | Capital Gain Distributions from Underlying Funds | |||||||||||||||||||||||||||
BlackRock Liquidity Funds, T-Fund, Institutional Class | $ | 27,581,316 | $ | — | $ | (968,932 | )(a) | $ | — | $ | — | $ | 26,612,384 | 26,612,384 | $ | 180,873 | $ | — | ||||||||||||||||||
SL Liquidity Series, LLC, Money Market Series | 211,489 | 482,609 | (a) | — | (86 | ) | 7 | 694,019 | 694,019 | 16,095 | (b) | — | ||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||||||
$ | (86 | ) | $ | 7 | $ | 27,306,403 | $ | 196,968 | $ | — | ||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
(a) | Represents net amount purchased (sold). |
(b) | All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities. |
Derivative Financial Instruments Outstanding as of Period End
Exchange-Traded Options Written
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||
Call | ||||||||||||||||||||||||
Genmab A/S, ADR | 64 | 10/03/22 | USD | 36.50 | USD | 206 | $ | (3 | ) | |||||||||||||||
Arcutis Biotherapeutics, Inc. | 55 | 10/04/22 | USD | 27.61 | USD | 105 | — | |||||||||||||||||
AmerisourceBergen Corp. | 2 | 10/07/22 | USD | 150.00 | USD | 27 | (150 | ) | ||||||||||||||||
Amgen, Inc. | 66 | 10/07/22 | USD | 245.00 | USD | 1,488 | (5,610 | ) | ||||||||||||||||
Baxter International, Inc. | 40 | 10/07/22 | USD | 59.00 | USD | 215 | (800 | ) | ||||||||||||||||
Biogen, Inc. | 75 | 10/07/22 | USD | 230.00 | USD | 2,003 | (290,250 | ) | ||||||||||||||||
Boston Scientific Corp. | 418 | 10/07/22 | USD | 42.00 | USD | 1,619 | (4,180 | ) | ||||||||||||||||
CVS Health Corp. | 38 | 10/07/22 | USD | 102.00 | USD | 362 | (266 | ) | ||||||||||||||||
Elevance Health, Inc. | 19 | 10/07/22 | USD | 495.00 | USD | 863 | (1,425 | ) | ||||||||||||||||
Eli Lilly & Co. | 209 | 10/07/22 | USD | 320.00 | USD | 6,758 | (179,740 | ) | ||||||||||||||||
Gilead Sciences, Inc. | 182 | 10/07/22 | USD | 64.00 | USD | 1,123 | (3,367 | ) | ||||||||||||||||
Intuitive Surgical, Inc. | 18 | 10/07/22 | USD | 220.00 | USD | 337 | (270 | ) | ||||||||||||||||
Johnson & Johnson | 155 | 10/07/22 | USD | 165.00 | USD | 2,532 | (20,692 | ) | ||||||||||||||||
McKesson Corp. | 17 | 10/07/22 | USD | 365.00 | USD | 578 | (1,615 | ) | ||||||||||||||||
Medtronic PLC | 65 | 10/07/22 | USD | 89.00 | USD | 525 | (390 | ) | ||||||||||||||||
Merck & Co., Inc. | 260 | 10/07/22 | USD | 90.00 | USD | 2,239 | (2,990 | ) | ||||||||||||||||
Pfizer, Inc. | 409 | 10/07/22 | USD | 48.00 | USD | 1,790 | (1,023 | ) | ||||||||||||||||
UnitedHealth Group, Inc. | 65 | 10/07/22 | USD | 540.00 | USD | 3,283 | (2,438 | ) | ||||||||||||||||
Abbott Laboratories | 255 | 10/14/22 | USD | 104.00 | USD | 2,467 | (6,247 | ) | ||||||||||||||||
Amgen, Inc. | 59 | 10/14/22 | USD | 255.00 | USD | 1,330 | (9,499 | ) | ||||||||||||||||
AstraZeneca PLC, ADR | 93 | 10/14/22 | USD | 61.00 | USD | 510 | (744 | ) | ||||||||||||||||
Baxter International, Inc. | 96 | 10/14/22 | USD | 58.00 | USD | 517 | (2,400 | ) | ||||||||||||||||
Boston Scientific Corp. | 409 | 10/14/22 | USD | 43.00 | USD | 1,584 | (6,135 | ) | ||||||||||||||||
Edwards Lifesciences Corp. | 36 | 10/14/22 | USD | 100.00 | USD | 297 | (1,620 | ) | ||||||||||||||||
Gilead Sciences, Inc. | 254 | 10/14/22 | USD | 65.00 | USD | 1,567 | (6,477 | ) | ||||||||||||||||
Intuitive Surgical, Inc. | 31 | 10/14/22 | USD | 215.00 | USD | 581 | (1,163 | ) | ||||||||||||||||
Johnson & Johnson | 338 | 10/14/22 | USD | 170.00 | USD | 5,522 | (22,139 | ) | ||||||||||||||||
Merck & Co., Inc. | 207 | 10/14/22 | USD | 88.00 | USD | 1,783 | (19,354 | ) | ||||||||||||||||
Moderna, Inc. | 53 | 10/14/22 | USD | 155.00 | USD | 627 | (875 | ) | ||||||||||||||||
Pfizer, Inc. | 411 | 10/14/22 | USD | 48.00 | USD | 1,799 | (2,672 | ) | ||||||||||||||||
10X Genomics, Inc., Class A | 16 | 10/21/22 | USD | 45.00 | USD | 46 | (1,760 | ) | ||||||||||||||||
Abbott Laboratories | 170 | 10/21/22 | USD | 115.00 | USD | 1,645 | (935 | ) | ||||||||||||||||
AbbVie, Inc. | 202 | 10/21/22 | USD | 150.00 | USD | 2,711 | (3,737 | ) | ||||||||||||||||
ABIOMED, Inc. | 29 | 10/21/22 | USD | 280.00 | USD | 712 | (3,697 | ) | ||||||||||||||||
Agilent Technologies, Inc. | 83 | 10/21/22 | USD | 140.00 | USD | 1,009 | (2,075 | ) | ||||||||||||||||
Alcon, Inc. | 69 | 10/21/22 | USD | 70.00 | USD | 401 | (1,725 | ) |
3 |
|
Schedule of Investments (unaudited) (continued) September 30, 2022 | BlackRock Health Sciences Trust (BME) |
Exchange-Traded Options Written (continued)
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||
Alkermes PLC | 24 | 10/21/22 | USD | 27.00 | USD | 54 | $ | (480 | ) | |||||||||||||||
Alkermes PLC | 20 | 10/21/22 | USD | 26.00 | USD | 45 | (150 | ) | ||||||||||||||||
Alnylam Pharmaceuticals, Inc. | 16 | 10/21/22 | USD | 234.00 | USD | 320 | (1,470 | ) | ||||||||||||||||
Alnylam Pharmaceuticals, Inc. | 43 | 10/21/22 | USD | 210.00 | USD | 861 | (25,155 | ) | ||||||||||||||||
Amedisys, Inc. | 26 | 10/21/22 | USD | 130.00 | USD | 252 | (3,900 | ) | ||||||||||||||||
Amedisys, Inc. | 19 | 10/21/22 | USD | 135.00 | USD | 184 | (9,120 | ) | ||||||||||||||||
AmerisourceBergen Corp. | 4 | 10/21/22 | USD | 145.00 | USD | 54 | (230 | ) | ||||||||||||||||
Arcutis Biotherapeutics, Inc. | 53 | 10/21/22 | USD | 30.00 | USD | 101 | (6,890 | ) | ||||||||||||||||
Arcutis Biotherapeutics, Inc. | 54 | 10/21/22 | USD | 25.00 | USD | 103 | (2,160 | ) | ||||||||||||||||
Argenx SE, ADR | 17 | 10/21/22 | USD | 384.00 | USD | 600 | (7,135 | ) | ||||||||||||||||
Avantor, Inc. | 230 | 10/21/22 | USD | 27.50 | USD | 451 | (2,300 | ) | ||||||||||||||||
Bausch & Lomb Corp. | 144 | 10/21/22 | USD | 17.50 | USD | 221 | (3,600 | ) | ||||||||||||||||
BioMarin Pharmaceutical, Inc. | 52 | 10/21/22 | USD | 97.00 | USD | 441 | (1,450 | ) | ||||||||||||||||
Blueprint Medicines Corp. | 20 | 10/21/22 | USD | 80.00 | USD | 132 | (1,650 | ) | ||||||||||||||||
Catalent, Inc. | 53 | 10/21/22 | USD | 100.00 | USD | 384 | (2,915 | ) | ||||||||||||||||
Cerevel Therapeutics Holdings, Inc. | 32 | 10/21/22 | USD | 40.00 | USD | 90 | (1,120 | ) | ||||||||||||||||
Cigna Corp. | 111 | 10/21/22 | USD | 290.00 | USD | 3,080 | (31,357 | ) | ||||||||||||||||
Design Therapeutics, Inc. | 10 | 10/21/22 | USD | 25.00 | USD | 17 | (275 | ) | ||||||||||||||||
DexCom, Inc. | 89 | 10/21/22 | USD | 96.05 | USD | 717 | (2,682 | ) | ||||||||||||||||
DexCom, Inc. | 105 | 10/21/22 | USD | 90.00 | USD | 846 | (11,287 | ) | ||||||||||||||||
Edwards Lifesciences Corp. | 89 | 10/21/22 | USD | 90.00 | USD | 735 | (7,120 | ) | ||||||||||||||||
Elevance Health, Inc. | 33 | 10/21/22 | USD | 510.00 | USD | 1,499 | (2,805 | ) | ||||||||||||||||
Enanta Pharmaceuticals, Inc. | 11 | 10/21/22 | USD | 70.00 | USD | 57 | (2,805 | ) | ||||||||||||||||
Encompass Health Corp. | 83 | 10/21/22 | USD | 55.00 | USD | 375 | (6,225 | ) | ||||||||||||||||
Exact Sciences Corp. | 58 | 10/21/22 | USD | 42.50 | USD | 188 | (4,350 | ) | ||||||||||||||||
Gilead Sciences, Inc. | 123 | 10/21/22 | USD | 65.00 | USD | 759 | (5,412 | ) | ||||||||||||||||
Glaukos Corp. | 10 | 10/21/22 | USD | 62.50 | USD | 53 | (650 | ) | ||||||||||||||||
Guardant Health, Inc. | 22 | 10/21/22 | USD | 65.00 | USD | 118 | (2,915 | ) | ||||||||||||||||
Henry Schein, Inc. | 53 | 10/21/22 | USD | 75.00 | USD | 349 | (795 | ) | ||||||||||||||||
Horizon Therapeutics PLC | 50 | 10/21/22 | USD | 69.00 | USD | 309 | (2,224 | ) | ||||||||||||||||
Icon PLC | 35 | 10/21/22 | USD | 240.00 | USD | 643 | (16,800 | ) | ||||||||||||||||
Immunocore Holdings PLC, ADR | 37 | 10/21/22 | USD | 55.00 | USD | 174 | (9,250 | ) | ||||||||||||||||
Insulet Corp. | 6 | 10/21/22 | USD | 290.00 | USD | 138 | (300 | ) | ||||||||||||||||
Ionis Pharmaceuticals, Inc. | 28 | 10/21/22 | USD | 50.00 | USD | 124 | (910 | ) | ||||||||||||||||
IQVIA Holdings, Inc. | 63 | 10/21/22 | USD | 250.00 | USD | 1,141 | (945 | ) | ||||||||||||||||
Karuna Therapeutics, Inc. | 13 | 10/21/22 | USD | 260.00 | USD | 292 | (3,413 | ) | ||||||||||||||||
Legend Biotech Corp., ADR | 26 | 10/21/22 | USD | 50.00 | USD | 106 | (1,885 | ) | ||||||||||||||||
McKesson Corp. | 39 | 10/21/22 | USD | 360.00 | USD | 1,325 | (10,432 | ) | ||||||||||||||||
Medtronic PLC | 65 | 10/21/22 | USD | 92.50 | USD | 525 | (358 | ) | ||||||||||||||||
Merck & Co., Inc. | 207 | 10/21/22 | USD | 87.50 | USD | 1,783 | (30,946 | ) | ||||||||||||||||
Neurocrine Biosciences, Inc. | 44 | 10/21/22 | USD | 110.00 | USD | 467 | (11,000 | ) | ||||||||||||||||
Nevro Corp. | 61 | 10/21/22 | USD | 55.00 | USD | 284 | (3,965 | ) | ||||||||||||||||
Novocure Ltd. | 20 | 10/21/22 | USD | 90.00 | USD | 152 | (2,350 | ) | ||||||||||||||||
Omnicell, Inc. | 12 | 10/21/22 | USD | 112.85 | USD | 104 | (1,901 | ) | ||||||||||||||||
Penumbra, Inc. | 20 | 10/21/22 | USD | 175.00 | USD | 379 | (39,300 | ) | ||||||||||||||||
Pfizer, Inc. | 337 | 10/21/22 | USD | 50.00 | USD | 1,475 | (1,854 | ) | ||||||||||||||||
QIAGEN NV | 78 | 10/21/22 | USD | 50.00 | USD | 322 | (1,560 | ) | ||||||||||||||||
Quest Diagnostics, Inc. | 16 | 10/21/22 | USD | 135.00 | USD | 196 | (760 | ) | ||||||||||||||||
Regeneron Pharmaceuticals, Inc. | 15 | 10/21/22 | USD | 650.00 | USD | 1,033 | (78,675 | ) | ||||||||||||||||
ResMed, Inc. | 39 | 10/21/22 | USD | 240.00 | USD | 851 | (6,337 | ) | ||||||||||||||||
Revolution Medicines, Inc. | 35 | 10/21/22 | USD | 25.00 | USD | 69 | (1,050 | ) | ||||||||||||||||
Rhythm Pharmaceuticals, Inc. | 69 | 10/21/22 | USD | 35.00 | USD | 169 | (1,208 | ) | ||||||||||||||||
Sage Therapeutics, Inc. | 20 | 10/21/22 | USD | 47.50 | USD | 78 | (500 | ) | ||||||||||||||||
Sarepta Therapeutics, Inc. | 59 | 10/21/22 | USD | 125.00 | USD | 652 | (8,260 | ) | ||||||||||||||||
Seagen, Inc. | 39 | 10/21/22 | USD | 175.00 | USD | 534 | (3,120 | ) | ||||||||||||||||
UnitedHealth Group, Inc. | 2 | 10/21/22 | USD | 540.00 | USD | 101 | (725 | ) | ||||||||||||||||
Vertex Pharmaceuticals, Inc. | 54 | 10/21/22 | USD | 300.00 | USD | 1,564 | (30,240 | ) | ||||||||||||||||
West Pharmaceutical Services, Inc. | 5 | 10/21/22 | USD | 340.00 | USD | 123 | (2,400 | ) | ||||||||||||||||
Zimmer Biomet Holdings, Inc. | 19 | 10/21/22 | USD | 120.00 | USD | 199 | (428 | ) | ||||||||||||||||
Zoetis, Inc. | 116 | 10/21/22 | USD | 175.00 | USD | 1,720 | (28,420 | ) | ||||||||||||||||
Abbott Laboratories | 59 | 10/28/22 | USD | 105.00 | USD | 571 | (4,189 | ) | ||||||||||||||||
AbbVie, Inc. | 104 | 10/28/22 | USD | 145.00 | USD | 1,396 | (11,856 | ) |
S C H E D U L E O F I N V E S T M E N T S | 4 |
Schedule of Investments (unaudited) (continued) September 30, 2022 | BlackRock Health Sciences Trust (BME) |
Exchange-Traded Options Written (continued)
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||
Align Technology, Inc. | 15 | 10/28/22 | USD | 280.00 | USD | 311 | $ | (2,738 | ) | |||||||||||||||
AmerisourceBergen Corp. | 153 | 10/28/22 | USD | 142.00 | USD | 2,071 | (28,305 | ) | ||||||||||||||||
Amgen, Inc. | 70 | 10/28/22 | USD | 245.00 | USD | 1,578 | (6,090 | ) | ||||||||||||||||
Baxter International, Inc. | 58 | 10/28/22 | USD | 57.00 | USD | 312 | (6,380 | ) | ||||||||||||||||
Biogen, Inc. | 74 | 10/28/22 | USD | 245.00 | USD | 1,976 | (212,750 | ) | ||||||||||||||||
Boston Scientific Corp. | 500 | 10/28/22 | USD | 40.00 | USD | 1,937 | (46,250 | ) | ||||||||||||||||
Bristol-Myers Squibb Co. | 241 | 10/28/22 | USD | 73.00 | USD | 1,713 | (30,125 | ) | ||||||||||||||||
Centene Corp. | 87 | 10/28/22 | USD | 81.00 | USD | 677 | (17,182 | ) | ||||||||||||||||
Cigna Corp. | 50 | 10/28/22 | USD | 290.00 | USD | 1,387 | (20,000 | ) | ||||||||||||||||
CVS Health Corp. | 53 | 10/28/22 | USD | 102.00 | USD | 505 | (3,286 | ) | ||||||||||||||||
Danaher Corp. | 137 | 10/28/22 | USD | 280.00 | USD | 3,539 | (36,990 | ) | ||||||||||||||||
Eli Lilly & Co. | 125 | 10/28/22 | USD | 325.00 | USD | 4,042 | (142,812 | ) | ||||||||||||||||
Intuitive Surgical, Inc. | 52 | 10/28/22 | USD | 235.00 | USD | 975 | (4,680 | ) | ||||||||||||||||
Medtronic PLC | 125 | 10/28/22 | USD | 90.00 | USD | 1,009 | (3,250 | ) | ||||||||||||||||
Moderna, Inc. | 58 | 10/28/22 | USD | 137.00 | USD | 686 | (14,877 | ) | ||||||||||||||||
Sarepta Therapeutics, Inc. | 6 | 10/28/22 | USD | 120.00 | USD | 66 | (2,250 | ) | ||||||||||||||||
Vertex Pharmaceuticals, Inc. | 55 | 10/28/22 | USD | 300.00 | USD | 1,592 | (46,750 | ) | ||||||||||||||||
Abbott Laboratories | 128 | 11/04/22 | USD | 105.00 | USD | 1,239 | (12,096 | ) | ||||||||||||||||
AbbVie, Inc. | 201 | 11/04/22 | USD | 145.00 | USD | 2,698 | (28,140 | ) | ||||||||||||||||
Amgen, Inc. | 60 | 11/04/22 | USD | 240.00 | USD | 1,352 | (13,680 | ) | ||||||||||||||||
Bristol-Myers Squibb Co. | 15 | 11/04/22 | USD | 75.00 | USD | 107 | (1,253 | ) | ||||||||||||||||
Centene Corp. | 182 | 11/04/22 | USD | 84.00 | USD | 1,416 | (27,300 | ) | ||||||||||||||||
Cigna Corp. | 11 | 11/04/22 | USD | 295.00 | USD | 305 | (5,170 | ) | ||||||||||||||||
CVS Health Corp. | 48 | 11/04/22 | USD | 101.00 | USD | 458 | (6,552 | ) | ||||||||||||||||
Danaher Corp. | 138 | 11/04/22 | USD | 280.00 | USD | 3,564 | (59,340 | ) | ||||||||||||||||
Elevance Health, Inc. | 50 | 11/04/22 | USD | 490.00 | USD | 2,271 | (30,750 | ) | ||||||||||||||||
Gilead Sciences, Inc. | 38 | 11/04/22 | USD | 67.00 | USD | 234 | (1,900 | ) | ||||||||||||||||
Intuitive Surgical, Inc. | 26 | 11/04/22 | USD | 205.00 | USD | 487 | (12,610 | ) | ||||||||||||||||
McKesson Corp. | 32 | 11/04/22 | USD | 365.00 | USD | 1,088 | (15,200 | ) | ||||||||||||||||
Medtronic PLC | 218 | 11/04/22 | USD | 84.00 | USD | 1,760 | (37,060 | ) | ||||||||||||||||
Merck & Co., Inc. | 151 | 11/04/22 | USD | 89.00 | USD | 1,300 | (26,651 | ) | ||||||||||||||||
Pfizer, Inc. | 241 | 11/04/22 | USD | 47.00 | USD | 1,055 | (13,978 | ) | ||||||||||||||||
Stryker Corp. | 100 | 11/04/22 | USD | 220.00 | USD | 2,025 | (28,000 | ) | ||||||||||||||||
Thermo Fisher Scientific, Inc. | 164 | 11/04/22 | USD | 540.00 | USD | 8,318 | (127,100 | ) | ||||||||||||||||
UnitedHealth Group, Inc. | 126 | 11/04/22 | USD | 545.00 | USD | 6,364 | (83,160 | ) | ||||||||||||||||
Vertex Pharmaceuticals, Inc. | 25 | 11/04/22 | USD | 300.00 | USD | 724 | (27,000 | ) | ||||||||||||||||
Agilent Technologies, Inc. | 43 | 11/09/22 | USD | 133.00 | USD | 523 | (7,274 | ) | ||||||||||||||||
Waters Corp. | 40 | 11/09/22 | USD | 288.00 | USD | 1,078 | (29,335 | ) | ||||||||||||||||
AmerisourceBergen Corp. | 44 | 11/11/22 | USD | 141.00 | USD | 595 | (13,200 | ) | ||||||||||||||||
Johnson & Johnson | 157 | 11/11/22 | USD | 170.00 | USD | 2,565 | (39,250 | ) | ||||||||||||||||
Sarepta Therapeutics, Inc. | 6 | 11/11/22 | USD | 125.00 | USD | 66 | (2,490 | ) | ||||||||||||||||
Stryker Corp. | 100 | 11/11/22 | USD | 220.00 | USD | 2,025 | (38,800 | ) | ||||||||||||||||
UnitedHealth Group, Inc. | 209 | 11/11/22 | USD | 540.00 | USD | 10,555 | (198,132 | ) | ||||||||||||||||
10X Genomics, Inc., Class A | 16 | 11/18/22 | USD | 40.00 | USD | 46 | (1,960 | ) | ||||||||||||||||
Abbott Laboratories | 128 | 11/18/22 | USD | 105.00 | USD | 1,239 | (17,984 | ) | ||||||||||||||||
ABIOMED, Inc. | 25 | 11/18/22 | USD | 280.00 | USD | 614 | (14,125 | ) | ||||||||||||||||
Agilent Technologies, Inc. | 110 | 11/18/22 | USD | 145.00 | USD | 1,337 | (6,050 | ) | ||||||||||||||||
Alcon, Inc. | 28 | 11/18/22 | USD | 72.50 | USD | 163 | (560 | ) | ||||||||||||||||
Alkermes PLC | 20 | 11/18/22 | USD | 27.00 | USD | 45 | (550 | ) | ||||||||||||||||
Amedisys, Inc. | 41 | 11/18/22 | USD | 130.00 | USD | 397 | (3,588 | ) | ||||||||||||||||
Argenx SE, ADR | 10 | 11/18/22 | USD | 410.00 | USD | 353 | (7,050 | ) | ||||||||||||||||
Avantor, Inc. | 69 | 11/18/22 | USD | 30.00 | USD | 135 | (1,035 | ) | ||||||||||||||||
BioMarin Pharmaceutical, Inc. | 63 | 11/18/22 | USD | 92.00 | USD | 534 | (15,637 | ) | ||||||||||||||||
Blueprint Medicines Corp. | 26 | 11/18/22 | USD | 80.00 | USD | 171 | (6,630 | ) | ||||||||||||||||
Boston Scientific Corp. | 127 | 11/18/22 | USD | 41.00 | USD | 492 | (11,747 | ) | ||||||||||||||||
Catalent, Inc. | 5 | 11/18/22 | USD | 100.50 | USD | 36 | (110 | ) | ||||||||||||||||
Cerevel Therapeutics Holdings, Inc. | 31 | 11/18/22 | USD | 35.00 | USD | 88 | (4,262 | ) | ||||||||||||||||
Cigna Corp. | 11 | 11/18/22 | USD | 300.00 | USD | 305 | (5,280 | ) | ||||||||||||||||
Cooper Cos., Inc. | 19 | 11/18/22 | USD | 320.00 | USD | 501 | (6,460 | ) | ||||||||||||||||
Design Therapeutics, Inc. | 15 | 11/18/22 | USD | 25.00 | USD | 25 | (6,150 | ) | ||||||||||||||||
Edwards Lifesciences Corp. | 35 | 11/18/22 | USD | 105.00 | USD | 289 | (1,225 | ) | ||||||||||||||||
Elevance Health, Inc. | 34 | 11/18/22 | USD | 510.00 | USD | 1,544 | (14,960 | ) |
5 |
|
Schedule of Investments (unaudited) (continued) September 30, 2022 | BlackRock Health Sciences Trust (BME) |
Exchange-Traded Options Written (continued)
Description | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | |||||||||||||||||||
Call (continued) | ||||||||||||||||||||||||
Encompass Health Corp. | 84 | 11/18/22 | USD | 53.75 | USD | 380 | $ | (14,415 | ) | |||||||||||||||
Guardant Health, Inc. | 22 | 11/18/22 | USD | 70.00 | USD | 118 | (9,460 | ) | ||||||||||||||||
HCA Healthcare, Inc. | 30 | 11/18/22 | USD | 230.00 | USD | 551 | (3,600 | ) | ||||||||||||||||
Horizon Therapeutics PLC | 25 | 11/18/22 | USD | 75.00 | USD | 155 | (2,313 | ) | ||||||||||||||||
Insulet Corp. | 13 | 11/18/22 | USD | 270.00 | USD | 298 | (6,565 | ) | ||||||||||||||||
IQVIA Holdings, Inc. | 30 | 11/18/22 | USD | 230.00 | USD | 543 | (3,150 | ) | ||||||||||||||||
iRhythm Technologies, Inc. | 8 | 11/18/22 | USD | 170.00 | USD | 100 | (1,220 | ) | ||||||||||||||||
Legend Biotech Corp., ADR | 27 | 11/18/22 | USD | 50.00 | USD | 110 | (4,927 | ) | ||||||||||||||||
Neurocrine Biosciences, Inc. | 44 | 11/18/22 | USD | 110.00 | USD | 467 | (19,580 | ) | ||||||||||||||||
Novocure Ltd. | 20 | 11/18/22 | USD | 95.00 | USD | 152 | (6,650 | ) | ||||||||||||||||
Omnicell, Inc. | 12 | 11/18/22 | USD | 110.00 | USD | 104 | (1,200 | ) | ||||||||||||||||
Penumbra, Inc. | 19 | 11/18/22 | USD | 204.00 | USD | 360 | (17,233 | ) | ||||||||||||||||
QIAGEN NV | 17 | 11/18/22 | USD | 50.00 | USD | 70 | (978 | ) | ||||||||||||||||
Quest Diagnostics, Inc. | 155 | 11/18/22 | USD | 130.00 | USD | 1,902 | (37,587 | ) | ||||||||||||||||
Regeneron Pharmaceuticals, Inc. | 11 | 11/18/22 | USD | 700.00 | USD | 758 | (41,030 | ) | ||||||||||||||||
Regeneron Pharmaceuticals, Inc. | 14 | 11/18/22 | USD | 720.00 | USD | 964 | (40,180 | ) | ||||||||||||||||
ResMed, Inc. | 39 | 11/18/22 | USD | 250.00 | USD | 851 | (12,577 | ) | ||||||||||||||||
Revolution Medicines, Inc. | 36 | 11/18/22 | USD | 25.00 | USD | 71 | (8,820 | ) | ||||||||||||||||
Rhythm Pharmaceuticals, Inc. | 67 | 11/18/22 | USD | 30.00 | USD | 164 | (11,557 | ) | ||||||||||||||||
Rhythm Pharmaceuticals, Inc. | 32 | 11/18/22 | USD | 35.00 | USD | 78 | (3,120 | ) | ||||||||||||||||
Sage Therapeutics, Inc. | 62 | 11/18/22 | USD | 47.50 | USD | 243 | (5,115 | ) | ||||||||||||||||
Seagen, Inc. | 39 | 11/18/22 | USD | 155.00 | USD | 534 | (21,255 | ) | ||||||||||||||||
Ultragenyx Pharmaceutical, Inc. | 23 | 11/18/22 | USD | 55.00 | USD | 95 | (2,185 | ) | ||||||||||||||||
Vertex Pharmaceuticals, Inc. | 25 | 11/18/22 | USD | 300.00 | USD | 724 | (27,250 | ) | ||||||||||||||||
West Pharmaceutical Services, Inc. | 5 | 11/18/22 | USD | 320.00 | USD | 123 | (325 | ) | ||||||||||||||||
Zimmer Biomet Holdings, Inc. | 18 | 11/18/22 | USD | 125.00 | USD | 188 | (1,350 | ) | ||||||||||||||||
Zoetis, Inc. | 166 | 11/18/22 | USD | 171.00 | USD | 2,462 | (16,679 | ) | ||||||||||||||||
Horizon Therapeutics PLC | 10 | 11/28/22 | USD | 72.50 | USD | 62 | (1,540 | ) | ||||||||||||||||
Insulet Corp. | 14 | 12/16/22 | USD | 260.00 | USD | 321 | (14,490 | ) | ||||||||||||||||
|
| |||||||||||||||||||||||
$ | (3,046,277 | ) | ||||||||||||||||||||||
|
|
OTC Options Written
Description | Counterparty | Number of Contracts | Expiration Date | Exercise Price | Notional Amount (000) | Value | ||||||||||||||||||||||||
Call | ||||||||||||||||||||||||||||||
Genmab A/S | Morgan Stanley & Co. International PLC | 900 | 10/06/22 | DKK | 2,830.88 | DKK | 2,215 | $ | (20 | ) | ||||||||||||||||||||
Hansoh Pharmaceutical Group Co. Ltd. | Morgan Stanley & Co. International PLC | 66,000 | 10/06/22 | HKD | 17.14 | HKD | 820 | — | ||||||||||||||||||||||
Daiichi Sankyo Co. Ltd. | JPMorgan Chase Bank N.A. | 7,000 | 10/12/22 | JPY | 3,781.05 | JPY | 28,294 | (14,587 | ) | |||||||||||||||||||||
Sanofi, ADR | JPMorgan Chase Bank N.A. | 15,500 | 10/14/22 | EUR | 97.96 | EUR | 1,215 | (18 | ) | |||||||||||||||||||||
Roche Holding AG | Goldman Sachs International | 1,100 | 10/18/22 | CHF | 332.63 | CHF | 356 | (4,050 | ) | |||||||||||||||||||||
Daiichi Sankyo Co. Ltd. | JPMorgan Chase Bank N.A. | 10,400 | 10/19/22 | JPY | 4,504.50 | JPY | 42,037 | (260 | ) | |||||||||||||||||||||
AstraZeneca PLC | Goldman Sachs International | 3,000 | 11/02/22 | GBP | 102.94 | GBP | 298 | (5,929 | ) | |||||||||||||||||||||
AstraZeneca PLC | Merrill Lynch International | 21,900 | 11/02/22 | GBP | 108.13 | GBP | 2,178 | (14,332 | ) | |||||||||||||||||||||
Zimmer Biomet Holdings, Inc. | Barclays Bank PLC | 1,800 | 11/02/22 | USD | 118.64 | USD | 188 | (1,153 | ) | |||||||||||||||||||||
Bausch & Lomb Corp. | Barclays Bank PLC | 14,400 | 11/03/22 | USD | 17.68 | USD | 221 | (4,372 | ) | |||||||||||||||||||||
Alcon, Inc. | Citibank N.A. | 6,900 | 11/04/22 | USD | 69.87 | USD | 401 | (1,020 | ) | |||||||||||||||||||||
Hansoh Pharmaceutical Group Co. Ltd. | UBS AG | 158,000 | 11/04/22 | HKD | 14.13 | HKD | 1,962 | (4,103 | ) | |||||||||||||||||||||
Alkermes PLC | Citibank N.A. | 1,900 | 11/09/22 | USD | 25.41 | USD | 42 | (831 | ) | |||||||||||||||||||||
Incyte Corp. | Barclays Bank PLC | 10,200 | 11/11/22 | USD | 71.43 | USD | 680 | (17,448 | ) | |||||||||||||||||||||
AstraZeneca PLC | JPMorgan Chase Bank N.A. | 3,600 | 11/15/22 | GBP | 102.92 | GBP | 358 | (9,601 | ) | |||||||||||||||||||||
Daiichi Sankyo Co. Ltd. | Morgan Stanley & Co. International PLC | 22,500 | 11/17/22 | JPY | 4,090.86 | JPY | 90,945 | (27,579 | ) | |||||||||||||||||||||
Ionis Pharmaceuticals, Inc. | JPMorgan Chase Bank N.A. | 2,900 | 11/17/22 | USD | 48.66 | USD | 128 | (4,552 | ) | |||||||||||||||||||||
Hansoh Pharmaceutical Group Co. Ltd. | UBS AG | 110,000 | 11/22/22 | HKD | 13.67 | HKD | 1,366 | (6,743 | ) | |||||||||||||||||||||
Roche Holding AG | Merrill Lynch International | 2,000 | 11/22/22 | CHF | 334.08 | CHF | 647 | (17,221 | ) | |||||||||||||||||||||
Alcon, Inc. | JPMorgan Chase Bank N.A. | 3,600 | 11/29/22 | USD | 68.51 | USD | 209 | (1,361 | ) | |||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
$ | (135,180 | ) | ||||||||||||||||||||||||||||
|
|
S C H E D U L E O F I N V E S T M E N T S | 6 |
Schedule of Investments (unaudited) (continued) September 30, 2022 | BlackRock Health Sciences Trust (BME) |
Fair Value Hierarchy as of Period End
Various inputs are used in determining the fair value of financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:
• | Level 1 – Unadjusted price quotations in active markets/exchanges for identical assets or liabilities that the Trust has the ability to access; |
• | Level 2 – Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market–corroborated inputs); and |
• | Level 3 – Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including the Valuation Committee’s assumptions used in determining the fair value of financial instruments). |
The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds. There may not be a secondary market, and/or there are a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust’s policy regarding valuation of financial instruments, refer to its most recent financial statements.
Certain investments of the Trust were fair valued using net asset value (“NAV”) per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy.
The following table summarizes the Trust’s financial instruments categorized in the fair value hierarchy. The breakdown of the Trust’s financial instruments into major categories is disclosed in the Schedule of Investments above.
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Assets | ||||||||||||||||
Investments | ||||||||||||||||
Long-Term Investments | ||||||||||||||||
Common Stocks | ||||||||||||||||
Biotechnology | $ | 100,129,764 | $ | 803,615 | $ | 84,645 | $ | 101,018,024 | ||||||||
Diversified Financial Services | 1,460,741 | — | — | 1,460,741 | ||||||||||||
Health Care Equipment & Supplies | 95,979,593 | — | — | 95,979,593 | ||||||||||||
Health Care Providers & Services | 124,133,731 | — | — | 124,133,731 | ||||||||||||
Life Sciences Tools & Services | 60,856,302 | — | — | 60,856,302 | ||||||||||||
Pharmaceuticals | 109,497,973 | 17,159,736 | — | 126,657,709 | ||||||||||||
Other Interests | — | — | 148,325 | 148,325 | ||||||||||||
Preferred Securities | ||||||||||||||||
Preferred Stocks | — | — | 4,458,076 | 4,458,076 | ||||||||||||
Warrants | 7,923 | — | — | 7,923 | ||||||||||||
Short-Term Securities | ||||||||||||||||
Money Market Funds | 26,612,384 | — | — | 26,612,384 | ||||||||||||
|
|
|
|
|
|
|
| |||||||||
$ | 518,678,411 | $ | 17,963,351 | $ | 4,691,046 | 541,332,808 | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Investments Valued at NAV(a) | 694,019 | |||||||||||||||
|
| |||||||||||||||
$ | 542,026,827 | |||||||||||||||
|
| |||||||||||||||
Derivative Financial Instruments(b) | ||||||||||||||||
Liabilities | ||||||||||||||||
Equity Contracts | $ | (2,927,189 | ) | $ | (254,268 | ) | $ | — | $ | (3,181,457 | ) | |||||
|
|
|
|
|
|
|
|
(a) | Certain investments of the Trust were fair valued using NAV per share as no quoted market value is available and therefore have been excluded from the fair value hierarchy. |
(b) | Derivative financial instruments are options written. Options written are shown at value. |
7 |
|
Schedule of Investments (unaudited) (continued) September 30, 2022 | BlackRock Health Sciences Trust (BME) |
Currency Abbreviation | ||
CHF | Swiss Franc | |
DKK | Danish Krone | |
EUR | Euro | |
GBP | British Pound | |
HKD | Hong Kong Dollar | |
JPY | Japanese Yen | |
USD | United States Dollar | |
Portfolio Abbreviation | ||
ADR | American Depositary Receipt |
S C H E D U L E O F I N V E S T M E N T S | 8 |